Clinical Trial Update: Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating LAS41005 for actinic keratosis has completed. Outcomes are not provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LAS41005

Snippet

Sponsor: Almirall, S.A. | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED